European Psychiatry - Volume 41 - April 2017

8 / 916

S4 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S3–S5
Lilly, Pfizer, BiolineRx, Roche, Abraham Pharmaceuticals, Pierre
Fabre, Minerva and Amgen.
Joint symposium: The value of treatment for brain
and mental disorders
JS003
Closing the treatment gap: The EPA
case study of schizophrenia
W. Gaebel
Heinrich-Heine-universität Düsseldorf, Germany
Introduction Schizophrenia still ranks among the first 10 leading
causes of disability worldwide. Recent analyses show that there
is a considerable treatment gap in schizophrenia in Europe and
worldwide.
Objectives To provide evidence-based information and give a
concise overview of what is needed to overcome the treatment gap
in schizophrenia.
Methods Using a combined approach of systematic review and
health economics was used to assess the socioeconomic impact of
medical interventions (or the lack of thereof) for schizophrenia.
Conclusions The case study analysis demonstrates socioeco-
nomic impact and health gains of best practices in specific
healthcare interventions for schizophrenia in comparison with the
cost burden of current care or non-treatment.
Disclosure of interest Unterstützung bei Symposien/Symposia
Support
– Janssen-Cilag GmbH, Neuss
– Aristo Pharma GmbH, Berlin
– Lilly Deutschland GmbH, Bad Homburg
– Servier Deutschland GmbH, München
– Fakultätsmitglied/Faculty Member
– Lundbeck International Neuroscience Foundation (LINF), Däne-
mark
JS004
The cost of non-treatment
M. Knapp
London School of Economics and Political Science, London, United
Kingdom
There are large treatment gaps in relation to schizophrenia across
all European countries, either because the illness is not recognised
or because the response from treatment and care services is inad-
equate - not evidence-based. This could be because of resource or
other constraints. The consequence can be very damaging indeed
for individuals with schizophrenia, their families and for the wider
society. In this talk I will set out the economic consequences of not
identifying or responding appropriately to schizophrenia. Evidence
will be drawn from a number of studies, but will be channelled to
show new findings in relation to both England and Czech Republic.
These figures add to the argument for earlier and better treatment,
to benefit everybody including public and private budgets.
Disclosure of interest The author has not supplied his declaration
of competing interest.
Joint symposium with the Italian psychiatric
association: Early intervention in psychotic
disorders: Comparing models and experiences
JS005
Assertive interventions for first
episode psychoses: The Danish
experience
M. Nordentoft ∗, N. Albert , C. Hjorthoj , H. Jensen , M. Melau
Mental health services in the capital region of Denmark, university of
Copenhagen, Denmark
∗ Corresponding author.
Early Intervention services with team-based intensive case man-
agement and family involvement are superior to standard
treatment in reducing psychotic and negative symptoms and
comorbid substance abuse and improving social functioning and
user satisfaction. The results of the OPUS-trial will be presented
togetherwithmeta-analyses based on similar trials. The implemen-
tation of OPUS all over Denmark will be presented together with
the Danish OPUS-fidelity study. Specialized elements are being are
being developed such as inclusion of new methods in CBT for psy-
chotic and negative symptoms, neurocognitive and social cognitive
training programs, interventions for supported employment and
focus on physical health. Results of long term follow-up studies
indicate that the prognosis of first episode psychosis is very diverse
with the extremes represented by one group being well function-
ing and able to quit medication without relapse; and another group
having a long term chronic course of illness with a need for sup-
port to maintain daily activities. The Danish TAILOR-trial–testing
dose reduction versus maintenance therapy will be presented. It
will be of immense value to be able to intervene in risk groups
identified in the premorbid phase, and there are few examples of
ongoing trial for children of parent with schizophrenia and bipolar
disorder.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
JS006
Assertive interventions for first
episode psychoses: The Italian
experience
A. Meneghelli
Solari 19, 20144, Milan, Italy
In Italy, despite the favourable conditions created by the 1978
reform law and the community psychiatry, at the end of the past
century there were no culture or initiatives oriented to innovative
and evidence-based founded interventions in early psychosis. The
watershed was the setting up in the MHD of Niguarda (Milan) of
Programma 2000, addressed to FEP and HR mostly inspired by
the knowledge of existing studies and experiences and with the
recommended characteristics of specificity, multicomponentiality,
assertiveness and doctrinal orientation. From the very start, one
fundamental aim was to disseminate information, training, super-
vision, and to raise consensus and initiatives throughout Italy, as
well as to improve international links. In many ways, the con-
sequences have been extremely positive. In 2005, Angelo Cocchi
and Programma 2000 team founded the AIPP (Italian Association
for Early Intervention in Psychosis), now named Italian Association
for Prevention and Early Intervention in Mental Health. Over the